Relative Bioavailability of Four Alternative Oral Formulations Versus the Current Tablet Formulation of Lapatinib.
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 19 Feb 2015
At a glance
- Drugs Lapatinib (Primary)
- Indications Cancer
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 15 Feb 2015 Status changed from suspended to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 12 Oct 2008 Status changed from discontinued to suspended as reported by ClinicalTrials.gov.
- 02 Sep 2008 Status changed from not yet recruiting to discontinued as reported by ClinicalTrials.gov.